OBM Genetics

(ISSN 2577-5790)

OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Archiving: full-text archived in CLOCKSS.

Publication Speed (median values for papers published in 2022): Submission to First Decision: 4 weeks; Submission to Acceptance: 12 weeks; Acceptance to Publication: 13 days (1-2 days of FREE language polishing included)

Current Issue: 2023  Archive: 2022 2021 2020 2019 2018 2017

Special Issue

Rare Genetic Syndromes: From Diagnosis to Treatment

Submission Deadline: November 30, 2024 (Open) Submit Now

Guest Editor

Fabrizio Stasolla, PhD, Professor

"Giustino Fortunato" University of Benevento, Benevento, Italy

Website | E-Mail

Research interests: autism spectrum disorders; Cerebral Palsy; Rare genetic syndromes (e.g. Angelman, Rett, Cornelia de Lange, fragile X); cognitive-behavioral interventions; Post-coma; Alzeimer; Parkinson; sclerosis neurodegenerative diseases; single-subject experimental designs

About This Topic

Children, adolescents, and young adults with rare genetic syndromes (e.g., Angelman, Down, Cornelia de Lange, Fragile X, Rett, and Williams syndromes) may experience significant problems while dealing with everyday life requests. Beside intellectual disabilities, communication disorders, motor impairments, and/or sensorial deficits may be included. An early diagnosis can be considered critical. Rehabilitative programs can be addressed accordingly.

This special issue will consider any type of paper (e.g., systematic reviews, scoping reviews, meta-analysis, empirical studies, randomized controlled trials, between groups comparisons, single-subject experimental studies, case-reports, and/or protocol studies) having individuals diagnosed with a rare genetic syndrome with both assessment and rehabilitative purposes as a basic target. Although technology-based interventions are privileged (i.e., assistive technology, new technologies as augmented and/or virtual reality setups, artificial intelligence settings, serious games, mobile and/or wearable technologies, telerehabilitation), any approaches (e.g., pharmacological or non-pharmacological, with behavioral and/or cognitive-behavioral therapies) are sought.